Australia is now one of the great life sciences hubs, and is ranked number four in biotechnology in the world. At last count, our 156 ASX-listed companies were valued at more than $161 billion. Despite the challenges of the global economy, Australia’s biotechnology and life sciences sector is doing very well, with an impressive return on investment from a maturing stock of companies.
Recognising that this niche industry was lacking an official publication, Executive Media has partnered with AusBiotech – Australia’s national biotechnology organisation and peak industry body – to produce its official publication, Australasian Biotechnology. This biannual journal features reports on research and business news within the biotechnology arena, innovation and clinical trials, medtech, regenerative medicines, and more.
Why advertise in Australasian Biotechnology?
With its informed and authoritative editorial, Australasian Biotechnology is a highly effective marketing and advertising vehicle for universities, research institutes and centres, and life sciences companies wanting to reach out to decision-makers in government and throughout all branches of the life sciences sector.
Australasian Biotechnology is mailed on a name-and-title basis to more than 2500 AusBiotech members. The journal also goes to high-net-worth companies and individuals with a particular focus on investment in life sciences. Readership includes government and university departments, research institutes, biotechnology and professional services providers nationally, and in key international life sciences hubs.Ask about advertising